Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
A newer version of this guideline has been published: Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology (2026)
- Study type
- Clinical guideline
- Study name
- NCCN Pancreatic Adenocarcinoma v2.2021
- Design
- Expert consensus-based clinical guideline (NCCN)
- Source
- Journal of the National Comprehensive Cancer Network · 2021
In plain words
This paper is the guideline of a large network of US cancer centres (NCCN) for diagnosing and treating pancreatic cancer. Because this disease is often found at an advanced stage, drug treatment is very important. Newer treatments, including targeted therapies, have raised hopes of better results. The choice of treatment should always be made with the treating doctor and based on each patient's situation.
Study population
Patients with pancreatic adenocarcinoma. This paper focuses specifically on systemic therapy approaches in locally advanced and metastatic disease.
Endpoints
The paper is a clinical guideline and has no trial endpoints. The guideline gives recommendations for the diagnosis, evaluation, treatment and follow-up of patients with pancreatic cancer.
Safety and side effects
The abstract gives no information on adverse effects. Details are in the full guideline.
Clinical significance and place in guidelines
This guideline provides a framework for the diagnosis, evaluation, treatment and follow-up of pancreatic cancer, and this version focuses on systemic therapy for locally advanced and metastatic disease. The abstract refers to targeted therapies as a promising approach. For exact recommendations and the current status of the guideline, the latest NCCN version should be consulted.
Limitations
The published abstract does not include specific recommendations, levels of evidence or doses; these must be taken from the full guideline. The guideline is updated, and version 2.2021 may no longer be current. The abstract notes that survival rates have remained relatively unchanged.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.